← Back to Clinical Trials
Recruiting NCT07632560

NCT07632560 CANUT Junior : Assessment of Sensory Abilities and Eating Behavior in Pediatric Oncology: a Feasibility Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07632560
Status Recruiting
Phase
Sponsor Centre Leon Berard
Condition Pediatric Hematologic Malignancies
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2024-12-13
Primary Completion 2024-12-13

Eligibility & Interventions

Sex All sexes
Min Age 7 Years
Max Age 17 Years
Study Type INTERVENTIONAL
Interventions
tests

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2024-12-13 with a primary completion date of 2024-12-13.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Cancer treatments in children are very intense and often cause side effects such as nausea, vomiting, loss of appetite, and changes in taste and smell. These sensory alterations can impact eating habits, but they are still poorly understood in children. The study aims to assess whether it is feasible to measure these sensory changes (taste, smell, salivation, and food preferences) in children and adolescents undergoing cancer treatment. This study is a feasibility study with 30 patients aged 7 to 17 years, treated at the Pediatric Hematology and Oncology Institute (IHOPE) in Lyon. Sensory tests and questionnaires to evaluate the perceptions, oral health, eating habits, nutritional status, and quality of life are used. The inclusion was initially planned at diagnosis, before any administration of chemotherapy. However, the study quickly encountered a recruitment problem due to the emotional impact and medical burden of this initial period of care (study offered to 11 families over a period of 5 months, 3 patients included). An amendment to the protocol was therefore made to be able to modify the inclusion period after the completion of chemotherapy. This modification was implemented on May 15, 2025, and allowed the inclusion of two new patients, making a total of 5 patients. Of these 5 patients, two completed all the tests during V0 and V1, two completed V0 but not V1, one did not complete any of the visits. This feasibility phase will help determine whether the tools are suitable and well accepted. The results will be used to design a larger study aimed at better understanding how taste and smell alterations influence the eating behaviors of young patients during cancer treatment. Recruitment will continue for six more months in order to reach the target number of participants.

Eligibility Criteria

Inclusion Criteria: * Patients treated at a pediatric oncology-hematology center, with an initial diagnosis of a solid or hematological tumor, aged 7 to 17 years inclusive. * Patients with functional oral feeding * Parent/guardian who has signed the informed consent form and patient who has not expressed refusal * Patients affiliated with the social security system * French-speaking patients * Validated indication for systematic oncological treatment Exclusion Criteria: * Individuals with a known food allergy/intolerance to the prototypes being studied (does not apply to patients on a protected diet) * Individuals who have undergone surgery on the tongue * Patients for whom other types of cancer treatment are planned during the study period (e.g., radiation therapy) * Patients with dental conditions * Patients who have relapsed

Contact & Investigator

Central Contact

Samia Saraya

✉ ssaraya-jean@institutlyfe.com

📞 +33767889375

Principal Investigator

Anestis Dougkas

STUDY DIRECTOR

Lyfe institute

Frequently Asked Questions

Who can join the NCT07632560 clinical trial?

This trial is open to participants of all sexes, aged 7 Years or older, up to 17 Years, studying Pediatric Hematologic Malignancies. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07632560 currently recruiting?

Yes, NCT07632560 is actively recruiting participants. Contact the research team at ssaraya-jean@institutlyfe.com for enrollment information.

Where is the NCT07632560 trial being conducted?

This trial is being conducted at Lyon, France.

Who is sponsoring the NCT07632560 clinical trial?

NCT07632560 is sponsored by Centre Leon Berard. The principal investigator is Anestis Dougkas at Lyfe institute. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology